Introduction
Accelerator mass spectrometry (AMS) has been used in many fields including archaeological anthropology, space and earth science, environmental science and new drug development. [1] [2] [3] Since AMS directly counts the amount of 14 C atoms in samples but does not measure radioactive decay events, the sensitivity of AMS is 1000 or more times higher than that of conventional methods such as liquid scintillation counting. 1) The AMS method has been validated and found to be as reliable as liquid scintillation counting. 1, 2) Due to its ultrasensitivity, AMS is often ap- The asterisk in the structure denotes the position labeled with 14 C in 14 C-R-142086.
plied to human microdosing studies using 14 C-labeled drugs. [3] [4] [5] [6] In this approach, because of the very small dose of 14 C-radioactivity, human exposure to radioactivity can be reduced to levels near to those caused by naturally occurring radiation. Since the dose of the drug is very low, typically not more than 100 mg/body, the need for extensive toxicological data to support an intravenous dose can be considerably decreased. [3] [4] [5] [6] Absolute bioavailability is usually assessed by oral and intravenous administrations to the same individual subjects in a crossover study. However, day-to-day variability in pharmacokinetics is a common problem due to separate administrations. Simultaneous administration of intravenous doses of a stable-isotope labeled drug along with an oral dose has been often used to overcome intraindividual variability in bioavailability. 7, 8) A simultaneous intravenous dose may interfer in the oral pharmacokinetics of non-labeled drugs. 9) Reducing the intravenous dose of stable-isotope labeled drugs circumvents such pharmacokinetic interference while extreme dose reduction will cause a sensitivity problem in drug analysis by conventional assay methods. However, by combination of AMS for the assay of 14 C-labeled drugs given intravenously at microdose levels and liquid chromatography with tandem mass spectrometry (LC-MS/MS) for the assay of non-labeled drugs given orally at therapeutic doses, absolute bioavailability of drugs can be evaluated by taking advantage of the high sensitivity of AMS. 12) Drug solubility may not be a concern in formulating the intravenous dose due to the minute dose of the 14 C-labeled drug utilized. 12) A small concern in this case, would be that there is little information on the reliability of AMS analysis compared to LC-MS/MS analysis for determination of drugs in plasma samples.
10)
R-142086 is an oral anti-factor Xa agent (Fig. 1) . R-142086 is highly hydrophilic, poorly absorbed and hardly metabolized in vivo in experimental animals. The absolute bioavailability of R-142086 in various species is low, from 5% in rats to 30% in dogs, and exhibits considerable inter-individual variation.
The present study evaluates simultaneous intravenous microdosing of 14 C-R-142086 (1.5 mg/kg) with oral dosing of R-142086 (1 mg/kg) for measurement of absolute bioavailability in dogs. Oral dosing of R-142086 at 1 mg/kg showed significant anti-factor Xa activity in dogs. For comparison, absolute bioavailability was evaluated either by the simultaneous administration of an intravenous microdose (1.5 mg/kg) with an oral dose or by separate administrations of an intravenous dose (0.3 mg/kg) and an oral dose. Also the correlation between the plasma concentration data obtained by AMS and those obtained by LC-MS/MS was examined. Since AMS determines only 14 C atoms without structure information, the absence of metabolites in the plasma was investigated chromatographically. AMS was also effectively used in detecting 14 C-content at an extremely low level in chromatography.
Materials and Methods
Materials: R-142086 was synthesized at DaiichiSankyo Co., Ltd (Tokyo, Japan). R-150176 ([   2   H3 ]-R-142086, isotope content º0.10%), the internal standard for the assay of R-142086 by LC-MS/MS, was synthesized at Chemtech Labo., Inc. (Tokyo, Japan). Figure 1 . The specific radioactivity was 1.14 GBq/mmol (47.5 mCi/mg), and radiochemical purity was guaranteed to be 98.5% by high performance liquid chromatography (HPLC). Prior to animal experiments, the radiochemical purity of 14 C-R-142086 in the dosing solution was also assayed to be more than 97%. All other reagents and solvents were of guaranteed, extra pure or HPLC grade.
Pharmacokinetic study: All animal studies described in this paper were approved by the DaiichiSankyo Research Laboratories Institutional Animal Care and Use Committee. Male Beagle dogs (n＝3) weighing 10.30 to 12.70 kg were obtained from Nihon Nosan Corporation (Kanagawa, Japan). Three studies, Study A, Study B and Study C, were performed in this order with a washing period of 7 days between Study A and Study B and between Study B and Study C. The dogs were fasted for about 18 h prior to administration in studies A, B and C, and a laboratory diet was given to the animols 8 h after each administration. During the experiments, the dogs had free access to tap water. In Study A, intravenous infusion of Blood samples (each 1 mL) were collected from a saphenous vein of the foreleg with a heparinized syringe before and at 15 min (0.25 h), 30 min (0.5 h), 1, 2, 4, 6, 8 and 24 h after starting the intravenous infusion. However, in Dog No. 1 in Study C, an additional blood sample was collected at 1.5 h since the infusion had to be prolonged from 1 h to 1.5 h due to instrumental error. The blood samples were centrifuged for 5 min at 49 C and 1,700×g to obtain plasma samples, which were stored frozen at -209 C until analyzed. The plasma concentrations of R-142086 determined by LC-MS/MS were expressed in units of ng/mL. Those of 14 C-R-142086 determined by AMS were divided by the specific radioactivity of 14 C-R-142086 and expressed in units of ng equivalent/mL (ng eq./mL). The mean 14 C-contents in the pre-dose plasma and urine samples collected from each dog were subtracted as background radioactivity from the observed data.
Regarding the dosing solutions, non-labeled R-142086 was dissolved in purified water at a concentration of 1 mg/mL for oral dosing. For intravenous microdosing, 14 C-R-142086 was dissolved in 20 mM isotonic acetate buffer (pH 5.0) at 1.5 mg/mL (71.25 nCi/mL). For intravenous dosing at 0.3 mg/kg, 14 C-R-142086 was diluted with 200-fold non-labeled R-142086 and the mixture was dissolved in 20 mM isotonic acetate buffer (pH 5.0) at 0.3 mg/mL (71.25 nCi/mL) as R-142086. For intravenous infusion, the jugular vein of each dog was cannulated with a polyethylene tube and the dosing solution was administered intravenously to each dog under unrestricted conditions over a period of 60 min at a constant rate using a motor driven syringe. Administration of the oral dosing solution was by gavage. Dosing volume was 1 mL/kg body weight for both oral and intravenous administrations.
HPLC-metabolic profiling of plasma and urine samples: Pooled plasma samples collected at 1 h and 4 h and the pooled urine samples collected at 24 h after starting the infusion of 14 C-R-142086 in Study A to three dogs were subjected to solid-phase extraction. The extracts were used for metabolic profiling by HPLC. For solid-phase extraction, each of the pooled plasma and pooled urine samples (500 mL) diluted with 2 mL of 2% acetic acid solution were each applied onto an Oasis HLB cartridge (3 cc/60 mg) (Waters Corporation, Milford, MA, USA), previously preconditioned with 1 mL methanol followed by 1 mL 2% acetic acid solution. After washing with 2 mL water, the column was eluted with 50% acetonitrile in water. The eluate was dried under a stream of nitrogen gas and reconstituted in 100 mL of mobile phase A for HPLC. Each solution of the sample extract was injected onto a 4.6 (i.d.)×150 mm YMCPack Hydrosphere C18 HS302 (5.0 mm) analytical column (YMC Co., Ltd., Kyoto, Japan) maintained at 409 C. A mixture of 50 mM phosphate buffer (pH 6.0) and ethanol (95/5, v/v) served as mobile phase A, and a mixture of 50 mM phosphate buffer (pH 6.0) and ethanol (70/30, v/v), as mobile phase B in HPLC. Elution was carried out in a linear gradient manner at a flow rate of 1 mL/min, starting at 100% in mobile phase A, with increase in mobile phase B from 0% to 30% over 20 min. The column eluent was collected at 1-min intervals and 14 C-content in each fraction was determined by AMS. The mean recovery of 14 C was more than 90% in the solid phase extraction and more than 95% in HPLC.
AMS analysis of total 14 C content in plasma: All biological samples were shipped from Daiichi-Sankyo Co., Ltd. to the Institute of Accelerator Analysis Ltd. on dry ice for AMS analysis. Sample preparation for AMS analysis was performed according to the method described by Kitagawa et al. with some modification. 11) NIST Oxalic acid and ANU sucrose, the AMS standard and process control, were purchased from the National Institute of Standards and Technology (NIST, Gaithersburg, USA) and Australian National University (ANU, Canberra, Australia), respectively. Synthetic graphite powder, depleted of 14 C, was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan) and used as the AMS machine background. Sodium benzoate was from Sigma-Aldrich (ST. Louis, USA) and used as carrier carbon and background in sample preparation processes. Plasma samples for AMS analysis were fivefold¿fiftyfold diluted with blank plasma based on radioactivity expected and an aliquot of 20 mL was placed into a pre-baked quartz ampoule tube (q6×20 mm, Koshin-RikagakuSeisakusyo, Ltd., Tokyo, Japan) with about 2 mg sodium benzoate as the carrier. To each HPLC fraction (20 mL or 100 mL), about 2 mg sodium benzoate were added as carrier carbon. After drying the sample at room temperature, the sample was converted to elemental carbon for AMS quantitation at 14 C in a two-stage process. The samples were first oxidized to CO2 gas in individual sealed tubes containing copper oxide (Kishida Chemical Co., Ltd., Osaka, Japan). The amount of carbon in each sample was calculated with the pressure of purified CO2 gas measured by a compact capacitance gauge. The purified CO2 gas was transformed to graphite by heating in an electric furnace at 6509 C onto approximately 2 mg iron powder (Sigma-Aldrich) and about twice as much pure H2 gas (Sumitomo Seika Chemicals Co., Ltd, Osaka, Japan) as CO2. Approximately one half the graphite (about 1 mg of carbon) was packed into an aluminum cathode (National Electrostatics Corporation, USA). To ensure the quality of sample preparation processes and confirm whether or not test samples were contaminated by other 14 C sources in the preparation processes, process controls (3 analytes) and carbon carriers (6 analytes) were prepared using the same procedures as for the test samples. The cathodes of the test samples were randomly placed into a 133-position AMS sample wheel with standards (3 cathodes), backgrounds (3 cathodes), process controls (3 cathodes) and 6 carbon carriers (3 cathodes). The sample wheel was inserted into the ion source (MS-SNICS) of the tandem electrostatic accelerator (NEC 1.5SDH-1 0.6MV Pelletron AMS system). About 300 seconds (3000 cycles) were required for one measurement and the ratio of where carbon content (gC/g or mL) in the sample was calculated from the amount of CO2 gas measured with a capacitance gauge. LC-MS/MS analysis of R-142086 in plasma: Assay of plasma concentration of unchanged R-142086 was performed by LC-MS/MS, which was validated in terms of precision, accuracy, and linearity. Plasma samples for LC-MS/MS analysis were cleaned up by solid-phase extraction using an Oasis HLB cartridge (1 cc/30 mg, Waters Corporation). Each sample (100 mL) diluted with 100 mL distilled water, 400 mL 2% acetic acid solution and 30 mL internal standard solution (R-150176) was applied onto the column preconditioned with 200 mL methanol followed by 300 mL 2% acetic acid solution. After washing with 300 mL distilled water, the column was eluted with 200 mL 50% acetonitrile in water. The eluates (10 mL) were analyzed on an API4000 mass spectrometer (Applied Biosystems, MDS SCIEX, Concord, ON, Canada) using TurboIonspray and selected ion monitoring. Separation by HPLC was performed using an Agilent 1100 HPLC System (Agilent Technologies, Santa Clara, CA, USA) with a 3.0 (i.d.)×50 mm Unison UK-Phenyl (3.0 mm) analytical column (Imtakt Corp., Kyoto, Japan) maintained at 409 C. The isocratic mobile phase was used at a flow rate of 0. ) to the fragment ion m/z 327 was monitored for R-142086 and transition of the protonated molecule m/z 290 to the fragment ion m/z 330 was monitored for the internal standard R-150176. Calibration standard solutions were prepared at final concentrations of 0.5-500 ng/mL as R-142086 concentrations using blank dog plasma. The method was validated and quality control acceptance criteria were applied, which indicated that inaccuracy in any case was loss than 15%.
Pharmacokinetic analysis: The plasma concentrations of R-142086 measured by LC-MS/MS and 14 C-content measured by AMS were analyzed by a non-compartmental model using the computer software WinNonlin Professional version 4.0.1. (Pharsight Corporation, Mountain View, CA, USA). The area under the plasma concentration-time curve (AUC, unit: ng･h/mL or ng eq. ･h/mL) up to the last measurable time point (AUC0-t) and AUC extrapolated to infinity (AUC0-inf) were calculated using the linear and log-linear trapezoidal rule. The elimination terminal half-life (t1/2, h), maximum plasma concentration observed (Cmax, ng/mL or ng eq./mL) and the time at which maximum concentration reached (Tmax, h) were also calculated. For intravenous dosing, total body clearance (CL, mL/h/kg) and the volume of distribution at steady state (Vdss, mL/kg) were calculated. The absolute bioavailability (F) of R-142086 after oral administration was determined from dose-adjusted AUC0-inf ratios based on AUC0-inf obtained in Study B and Study C. Data on the pharmacokinetic parameters represent the mean value of 3 animals with the standard deviation. 
Results
Pharmacokinetics of 14 C-R-142086 and R-142086: Pharmacokinetic parameters for 14 C-R-142086 and R-14208 after intravenous administration are shown in Table 1 (Study A, B and C) and those for R-142086 after oral or intravenous administration are shown in Table 2 (Study B). AUC0-inf of 14 C-R-142086 after intravenous microdosing was not affected by the simultaneous oral administration of R-142086 at 1 mg/kg (4.30 ng eq.･h/mL in Study A vs. 3.86 ng eq.･h/mL in Study B). CL and Vdss values of 14 C-R-142086 after intravenous microdosing were not affected by the simultaneous oral administration of R-142086 at 1 mg/kg (350 mL/h/kg and 1090 mL/kg in Study A vs. 395 mL/h/kg and 1150 mL/h/kg in Study B). CL and Vdss values of 14 C-R-142086 after intravenous administration were comparable at doses of 1.5 mg/kg (microdose) and 0.3 mg/kg (350 mL/h/kg and 1090 mL/kg in Study A vs. 376 mL/h/kg and 1110 mL/kg in Study C). Plasma concentration-time curves for 14 C-R-142086 determined by AMS, each dose-normalized to 1 mg/kg, are compared in Figure 2 and were found to exhibit very similar time courses.
Metabolic profiling of serum and urine: Metabolites in plasma samples collected at 1 h and 4 h, and pooled urine collected at 24 h after intravenous microdosing of 14 C-R-142086 (Study A) were analyzed by HPLC-AMS (Fig. 3) . There was only one radioactivity peak at the same retention time as that of 14 C-R-142086 in the chromatograms, although there were several baseline noise levels in the responses. These results suggest that the unchanged 14 C-R-142086 accounted for almost all the radioactivity present in both the plasma and urine and that R-142086 is hardly metabolized in dogs after intravenous administration. Thus, in the present study, the plasma concentrations of 14 C-R-142086 analyzed by AMS may be regarded as those of the unchanged R-142086 to make comparison with LC-MS/MS analysis simpler.
Cross-comparison of AMS and LC-MS/MS analyses for assay of plasma concentration: Plasma concentrations after an intravenous dose (0.3 mg/kg, 71.25 nCi/kg, Study C) to dogs were determined by both LC-MS/MS and AMS. The plasma samples were analyzed by AMS after fivefold¿fiftyfold dilution, whereas the undiluted plasma samples were analyzed by LC-MS/MS. The plasma concentrations-time curves for 14 C-R-142086 determined by AMS and for R-142086 determined by LC-MS/MS in each dog are compared in Figure 4 (Panel A), and were found to exhibit almost the same time courses. The plasma concentrations of R-142086 determined by LC-MS/MS were slightly higher than those of 14 C-R-142086 determined by AMS, except at the lowest points, resulting in slight differences of approximately 20% in Cmax, AUC0-inf and CL obtained by LC-MS/MS and AMS ( Table 1) . In Figure 4 (Panel B), log-transformed were 15.1% and 12.5%, respectively ( Table 2) . Intervariation was slightly less in Fsiml (1.9% in SD and 11.8% in CV) than in FLC-MS/MS (2.4% in SD and 19.2% in CV), although the difference was statistically insignificant.
Discussion
As far as we know, the present study is the first to directly compare AMS analysis with LC-MS/MS analysis by evaluating absolute bioavailability after simultaneous administration of intravenous microdosing of 14 C-drug and oral dosing of an unlabeled drug, with plasma concentra- tion profiles determined by AMS and LC-MS/MS, respectively. A human microdosing study may have potential for the early evaluation of the human pharmacokinetic properties of drug candidates. The simultaneous intravenous microdosing of 14 C-drug in conjunction with oral dosing of a non-labeled drug is useful to evaluate absolute bioavailability for the following reasons. (1) Absolute bioavailability can be evaluated without large day-today variation in pharmacokinetics. 7, 8) (2) Concern over the solubility of drugs required for intravenous dosing can be much reduced. 4, 12) (3) No confirmation of pharmacokinetic linearity for the intravenous dose is required because a 14 C-labeled tracer dose follows the same clearance-time course as a non-labeled drug from an oral dose. 9, 12) (4) Only minimal toxicological data to support an intravenous dose for humans is required. [3] [4] [5] [6] It is possible to evaluate not only pharmacokinetic parameters but also drug mass valance and metabolite profiles, as well as their relevance to observed pharmacokinetic parameters after intravenous dosing at an oral dose level. As most drug candidates are not assessed for bioavailability in humans, the use of microdosing substantially improves our understanding of drugs, thereby facilitating optimal decision-making during clinical development.
In the present study, the reliability of the simultaneous microdosing technique for absolute bioavailability was assessed using R-142086, a highly hydrophilic, poorly absorbed and hardly metabolized drug. The oral absolute bioavailability was evaluated by three kinds of data obtained from intravenous administration. Bioavailability ranged from 12% to 16% regardless of the method used ( Table 2) . Plasma concentrations of R-142086 determined by LC-MS/MS were slightly higher than those of 14 C-R-142086 determined by AMS, except at the lowest point, after intravenous administration at 0.3 mg/kg ( Table 1 and Fig. 4) . This seems to cause slight difference in the bioavailability of R-142086 between Fsiml (16.1%) and FLC-MS/MS (12.5%), as shown in Table 2 . Intervariation was slightly smaller in Fsiml (1.9% in SD and 11.8% in CV) than in FLC-MS/MS (2.4% in SD and 19.2% in CV), although the difference was statistically insignificant. post-dose. In the next study, to accurately measure plasma concentrations of unchanged 14 C-labeled drug, it may be better for each plasma concentration of total 14 C to be corrected by both the ratios of the unchanged form analyzed by HPLC-AMS and recovery from extraction and HPLC in each plasma sample, even if the drug is hardly metabolized.
In conclusion, in a pharmacokinetic study of R-142086 in dogs, plasma concentrations determined by AMS analysis were basically the same as those determined by LC-MS/MS, with a slight difference of 20%. Utilizing simultaneous intravenous microdosing of 14 C-labeled drug with AMS analysis, not only absolute bioavailability, but also total clearance and distribution volume at an oral dose level could be approximately measured in dogs, but without total accuracy. Bioavailability in humans may be approximately measured at an earlier stage at lower cost.
